Sino Biopharmaceutical Limited has announced that its innovative drug, TQC3721 inhalation suspension, a PDE3/4 inhibitor, has received approval from the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China to commence a phase III registrational clinical study. This study aims to explore the maintenance treatment for chronic obstructive pulmonary disease (COPD). TQC3721, known for its bronchodilatory and anti-inflammatory effects, is noted for its advanced research and development progress, ranking second worldwide. This phase III trial will include patients with dual bronchodilators as part of their background treatment, broadening its scope to cover a wider range of COPD patients. Additionally, an inhaled dry powder formulation of TQC3721 is in phase I clinical development, expected to enhance patient compliance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。